Gilder Gagnon Howe & Co. LLC boosted its position in BioScrip, Inc. (NASDAQ:BIOS) by 3.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 15,764,337 shares of the company’s stock after purchasing an additional 553,201 shares during the quarter. Gilder Gagnon Howe & Co. LLC owned approximately 12.36% of BioScrip worth $43,352,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the business. FMR LLC raised its holdings in BioScrip by 10.8% in the second quarter. FMR LLC now owns 5,323,231 shares of the company’s stock worth $14,453,000 after purchasing an additional 520,231 shares in the last quarter. Vanguard Group Inc. raised its holdings in BioScrip by 3.4% in the second quarter. Vanguard Group Inc. now owns 4,495,029 shares of the company’s stock worth $12,204,000 after purchasing an additional 146,980 shares in the last quarter. Alta Fundamental Advisers LLC raised its holdings in BioScrip by 36.9% in the second quarter. Alta Fundamental Advisers LLC now owns 3,035,164 shares of the company’s stock worth $8,240,000 after purchasing an additional 818,000 shares in the last quarter. State Street Corp raised its holdings in BioScrip by 10.0% in the second quarter. State Street Corp now owns 1,815,439 shares of the company’s stock worth $4,927,000 after purchasing an additional 165,091 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in shares of BioScrip by 11.3% during the second quarter. Northern Trust Corp now owns 1,340,339 shares of the company’s stock valued at $3,639,000 after acquiring an additional 136,187 shares in the last quarter. Institutional investors and hedge funds own 83.00% of the company’s stock.
Several equities analysts have recently issued reports on the stock. ValuEngine upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a report on Monday, August 14th. SunTrust Banks, Inc. restated a “buy” rating and set a $3.00 price objective on shares of BioScrip in a report on Friday, November 3rd. BidaskClub downgraded shares of BioScrip from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 1st. Zacks Investment Research downgraded shares of BioScrip from a “buy” rating to a “hold” rating in a report on Monday, August 14th. Finally, Jefferies Group LLC restated a “buy” rating and set a $4.00 price objective (up previously from $3.00) on shares of BioScrip in a report on Thursday, August 10th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $3.60.
In other BioScrip news, Director Coliseum Capital Management, L sold 2,846,941 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $2.93, for a total value of $8,341,537.13. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Michael G. Bronfein sold 27,000 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $2.69, for a total value of $72,630.00. Following the completion of the sale, the director now owns 129,669 shares in the company, valued at approximately $348,809.61. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,760,419 shares of company stock worth $11,144,519. Insiders own 0.80% of the company’s stock.
Shares of BioScrip, Inc. (NASDAQ BIOS) traded up $0.03 during trading hours on Monday, reaching $2.11. 781,900 shares of the company traded hands, compared to its average volume of 1,086,750. BioScrip, Inc. has a one year low of $0.98 and a one year high of $3.39. The company has a debt-to-equity ratio of -6.11, a quick ratio of 1.60 and a current ratio of 1.91.
BioScrip (NASDAQ:BIOS) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.02). The company had revenue of $198.70 million for the quarter, compared to the consensus estimate of $202.91 million. During the same quarter in the previous year, the business posted ($0.12) EPS. The company’s revenue for the quarter was down 11.5% compared to the same quarter last year. analysts forecast that BioScrip, Inc. will post -0.63 earnings per share for the current year.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Want to see what other hedge funds are holding BIOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioScrip, Inc. (NASDAQ:BIOS).
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.